Ads by Google

Drug Clinical Trials

Vaccine To Treat Nicotine Addiction Achieves Proof of Efficacy in Phase II Clinical Trial

Efficacy of the vaccine was determined by continuous abstinence from smoking between week 8 and 24 after treatment start and was measured by self-reporting of the participating smokers.

Cytos Biotechnology AG (SWX:CYTN) announced today that its vaccine candidate CYT002-NicQb to treat nicotine addiction has achieved proof of efficacy. The phase II clinical trial results were presented by Prof. Dr. Jacques Cornuz (CHUV Lausanne), principal investigator, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, USA, on behalf of the three Swiss study centres.

Health and Wellness: 

Researchers Confirm Vioxx Nearly Doubled Cardiovascular Risks in Cancer Prevention Study

The largest prospective trial ever examining the anti-inflammatory drug Vioxx as a chemoprevention agent found that the risk of developing a cardiovascular "event," heart attacks and/or strokes, was almost double in patients who received the drug.

Health and Wellness: 

Pages